Clinical and Diagnostic Laboratory Immunology

Journal

Publication Venue For

  • The pneumococcal serotype 15C capsule is partially O-acetylated and allows for limited evasion of 23-valent pneumococcal polysaccharide vaccine-elicited anti-serotype 15B antibodies.  24. 2017
  • Plasmablast response to primary rhesus cytomegalovirus (CMV) infection in a monkey model of congenital CMV transmission.  24. 2017
  • The predominant CD4+ Th1 cytokine elicited to chlamydia trachomatis infection in women is tumor necrosis factor alpha and not interferon gamma.  24. 2017
  • Assignment of opsonic values to pneumococcal reference serum 007sp for use in opsonophagocytic assays for 13 serotypes.  24. 2017
  • The live attenuated cholera vaccine CVD 103-HgR primes responses to the toxin-coregulated pilus antigen TcpA in subjects challenged with wild-type vibrio cholerae.  24. 2017
  • Monoclonal antibodies to Shigella lipopolysaccharide are useful for vaccine production.  23:681-688. 2016
  • Resolution of Chlamydia trachomatis infection is associated with a distinct T cell response profile.  22:1206-1218. 2015
  • Multivalent pneumococcal protein vaccines comprising pneumolysoid with epitopes/fragments of CbpA and/or PspA elicit strong and broad protection.  22:1079-1089. 2015
  • Evaluation of a vaccine formulation against Streptococcus pneumoniae based on choline-binding proteins..  22:213-220. 2015
  • Genetic, biochemical, and serological characterization of a new pneumococcal serotype, 6H, and generation of a pneumococcal strain producing three different capsular repeat units.  22:313-318. 2015
  • Safety and immunogenicity of escalating dosages of a single oral administration of peru-15 pCTB, a candidate live, attenuated vaccine against enterotoxigenic Escherichia coli and Vibrio cholerae.  22:129-135. 2015
  • Commercially available complement component-depleted sera are unexpectedly codepleted of ficolin-2.  21:1323-1329. 2014
  • Novel catanionic surfactant vesicle vaccines protect against Francisella tularensis LVS and confer significant partial protection against F. tularensis Schu S4 strain.  21:212-226. 2014
  • Blood collection tubes influence serum ficolin-1 and ficolin-2 levels.  21:51-55. 2014
  • Mapping of epitopes recognized by antibodies induced by immunization of mice with PspA and PspC.  21:940-948. 2014
  • Phase i/ii randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-Uninfected adult participants.  21:1589-1599. 2014
  • Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli (Clinical and Vaccine Immunology (2013) 20, 11, (1764-1770)).  21:602. 2014
  • Invasive and Noninvasive Streptococcus pneumoniae Capsule and Surface Protein Diversity following the Use of a Conjugate Vaccine.  20:1711-1718. 2013
  • Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli.  20:1764-1770. 2013
  • A single intraduodenal administration of human adenovirus 40 vaccine effectively prevents anaphylactic shock.  20:1508-1516. 2013
  • Modified opsonization, phagocytosis, and killing assays to measure potentially protective antibodies against pneumococcal surface protein A.  20:1549-1558. 2013
  • The absence of PspA or presence of antibody to PspA facilitates the complement-dependent phagocytosis of pneumococci In Vitro.  19:1574-1582. 2012
  • Device for carrying blood samples at 37°C for cryoglobulin test.  19:1555-1556. 2012
  • Impaired function of antibodies to pneumococcal surface protein A but Not to capsular polysaccharide in Mexican American adults with type 2 diabetes mellitus.  19:1360-1369. 2012
  • Development of a fourfold multiplexed opsonophagocytosis assay for pneumococcal antibodies against additional serotypes and discovery of serological subtypes in Streptococcus pneumoniae serotype 20.  19:835-841. 2012
  • PspA family distribution, unlike capsular serotype, remains unaltered following introduction of the heptavalent pneumococcal conjugate vaccine.  19:891-896. 2012
  • Strain-specific neutralizing antibody responses against human cytomegalovirus envelope glycoprotein N.  19:909-913. 2012
  • Development of an automated and multiplexed serotyping assay for Streptococcus pneumoniae.  18:1900-1907. 2011
  • Establishment of a new human pneumococcal standard reference serum, 007sp.  18:1728-1736. 2011
  • Histoplasma antigen clearance during treatment of histoplasmosis in patients with AIDS determined by a quantitative antigen enzyme immunoassay.  18:661-666. 2011
  • Multilaboratory comparison of Streptococcus pneumoniae opsonophagocytic killing assays and their level of agreement for the determination of functional antibody activity in human reference sera.  18:135-142. 2011
  • PsrP, a protective pneumococcal antigen, is highly prevalent in children with pneumonia and is strongly associated with clonal type.  17:1672-1678. 2010
  • Expression of homing receptors on IgA1 and IgA2 plasmablasts in blood reflects differential distribution of IgA1 and IgA2 in various body fluids.  17:393-401. 2010
  • Lipoprotein lipase and hydrofluoric acid deactivate both bacterial lipoproteins and lipoteichoic acids, but platelet-activating factor-acetylhydrolase degrades only lipoteichoic acids.  16:1187-1195. 2009
  • Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A.  16:376-381. 2009
  • Enzyme-linked immunosorbent assay method for detection of cytomegalovirus strain-specific antibody responses.  16:288-290. 2009
  • Development of antibodies to PspA families 1 and 2 in children after exposure to Streptococcus pneumoniae.  15:1529-1535. 2008
  • Distribution of pneumococcal surface protein A families 1 and 2 among Streptococcus pneumoniae isolates from children in Finland who had acute otitis media or were nasopharyngeal carriers.  15:1555-1563. 2008
  • Seroincidence of recent human immunodeficiency virus type 1 infections in China.  14:1384-1386. 2007
  • Evaluation of the LIAISON chemiluminescence immunoassay for diagnosis of syphilis.  14:710-713. 2007
  • Serum antibodies to pneumococcal neuraminidase NanA in relation to pneumococcal carriage and acute otitis media.  13:1177-1179. 2006
  • Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies.  13:1004-1009. 2006
  • Platelet-activating factor-acetylhydrolase can monodeacylate and inactivate lipoteichoic acid.  13:452-458. 2006
  • Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines.  13:165-169. 2006
  • Use of HL-60 cell line to measure opsonic capacity of pneumococcal antibodies.  12:19-27. 2005
  • Multilaboratory Evaluation of a Viability Assay for Measurement of Opsonophagocytic Antibodies Specific to the Capsular Polysaccharides of Streptococcus pneumoniae.  10:1019-1024. 2003
  • Efficiency of a pneumococcal opsonophagocytic killing assay improved by multiplexing and by coloring colonies.  10:616-621. 2003
  • Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides.  10:514-519. 2003
  • TH1 and TH2 cytokine mRNA and protein levels in human immunodeficiency virus (HIV)-seropositive and HIV-seronegative youths.  10:399-404. 2003
  • Assessment of thymic activity in human immunodeficiency virus-negative and -positive adolescents by real-time PCR quantitation of T-cell receptor rearrangement excision circles.  10:323-328. 2003
  • Peripheral blood lymphocyte subsets in adolescents: A longitudinal analysis from the REACH project.  9:959-965. 2002
  • Chromogenic assay measuring opsonophagocytic killing capacities of antipneumococcal antisera.  8:528-533. 2001
  • Comparison of a classical phagocytosis assay and a flow cytometry assay for assessment of the phagocytic capacity of sera from adults vaccinated with a pneumococcal conjugate vaccine.  8:245-250. 2001
  • Performance of antigens used in detecting delayed-type hypersensitivity in adolescents infected with the human immunodeficiency virus.  8:273-278. 2001
  • A latex bead-based flow cytometric immunoassay capable of simultaneous typing of multiple pneumococcal serotypes (multibead assay).  7:486-489. 2000
  • Towards a synthetic pneumococcal vaccine: Synthetic oligosaccharides as tools for improving the specificity of enzyme-linked immunosorbent assays [1] (multiple letters).  7:325. 2000
  • Successful treatment of fluconazole-resistant oropharyngeal candidiasis by a combination of fluconazole and terbinafine.  6:921-923. 1999
  • Pneumococcal capsular polysaccharide preparations may contain non-C- polysaccharide contaminants that are immunogenic.  6:519-524. 1999
  • Reconstruction of the immune system after unrelated or partially matched T-cell-depleted bone marrow transplantation in children: Functional analyses of lymphocytes and correlation with immunophenotypic recovery following transplantation.  4:96-103. 1997
  • Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines.  3:378-386. 1996
  • Humoral antibody to Mobiluncus curtisii, a potential serological marker for bacterial vaginosis.  3:567-569. 1996
  • International Standard Serial Number (issn)

  • 1071-412X
  • 1556-6811
  • Electronic International Standard Serial Number (eissn)

  • 1556-679X